Administration of enoxaparin 24 h after total knee arthroplasty: safer for bleeding and equally effective for deep venous thrombosis prevention
The purpose of this study was to determine the safety and effectiveness, as assessed by risk of bleeding and incidence of deep venous thrombosis (DVT), of administering delayed low-molecular-weight heparin (LMWH) after total knee arthroplasty.
A prospective study of 210 consecutive patients undergoing primary unilateral total knee arthroplasty was undertaken. The patients were randomized into two groups: one of which was managed according to a standard LMWH program (LMWH-s group) and the other with delayed LMWH (LMWH-p). LMWH was initiated 12 h after wound closure in the LMWH-s group, and 24 h after wound closure in the LMWH-p group.
The total blood loss in the first three postoperative days was calculated and all complications were recorded. The mean total blood loss was 435 and 387 mL in the LMWH-s group and LMWH-p group, respectively (p < 0.01). No significant difference in the incidence of symptomatic DVT was observed. The mean length of hospital stay was 7.29 days in the LMWH-s group and 6.56 days in the LMWH-p group (p < 0.05).
After total knee arthroplasty, LMWH-p is safer for bleeding than LMWH-s and equally effective concerning prevention of DVT.
KeywordsDeep venous thrombosis Low-molecular-weight heparin Medication Anticoagulation Total blood loss
- 3.Lie SA, Engesaeter LB, Havelin LI, Furnes O, Vollset SE (2002) Early postoperative mortality after 67,548 total hip replacements: causes of death and thromboprophylaxis in 68 hospitals in Norway from 1987 to 1999. Acta Orthop Scand 73(4):392–399. doi:10.1080/00016470216312 PubMedCrossRefGoogle Scholar
- 6.Kakkar AK, Brenner B, Dahl OE, Eriksson BI, Mouret P, Muntz J, Soglian AG, Pap AF, Misselwitz F, Haas S (2008) Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomised controlled trial. Lancet 372(9632):31–39. doi:10.1016/S0140-6736(08)60880-6 PubMedCrossRefGoogle Scholar
- 7.Turpie AG, Lassen MR, Eriksson BI, Gent M, Berkowitz SD, Misselwitz F, Bandel TJ, Homering M, Westermeier T, Kakkar AK (2011) Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty. Pooled analysis of four studies. Thromb Haemost 105(3):444–453. doi:10.1160/TH10-09-0601 PubMedGoogle Scholar
- 11.Hull R, Raskob G, Pineo G, Rosenbloom D, Evans W, Mallory T, Anquist K, Smith F, Hughes G, Green D et al (1993) A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation. N Engl J Med 329(19):1370–1376. doi:10.1056/NEJM199311043291902 PubMedCrossRefGoogle Scholar
- 12.RD Heparin Arthroplasty Group (1994) RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty. J Bone Joint Surg Am 76(8):1174–1185Google Scholar
- 14.Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Buller HR (2007) Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 370(9591):949–956. doi:10.1016/S0140-6736(07)61445-7 PubMedCrossRefGoogle Scholar
- 21.Fitzgerald RH, Spiro TE, Trowbridge AA, Gardiner GA, Whitsett TL, O’Connell MB, Ohar JA, Young TR (2001) Prevention of venous thromboembolic disease following primary total knee arthroplasty. A randomized, multicenter, open-label, parallel-group comparison of enoxaparin and warfarin. J Bone Joint Surg Am 83-A(6):900–906PubMedGoogle Scholar
- 27.Nieto JA, Espada NG, Merino RG, Gonzalez TC (2012) Dabigatran, rivaroxaban and apixaban versus enoxaparin for thomboprophylaxis after total knee or hip arthroplasty: pool-analysis of phase III randomized clinical trials. Thromb Res 130(2):183–191. doi:10.1016/j.thromres.2012.02.011 PubMedCrossRefGoogle Scholar
- 28.McCullagh L, Tilson L, Walsh C, Barry M (2009) A cost-effectiveness model comparing rivaroxaban and dabigatran etexilate with enoxaparin sodium as thromboprophylaxis after total hip and total knee replacement in the irish healthcare setting. Pharmacoeconomics 27(10):829–846. doi:10.2165/11313800-000000000-00000 PubMedCrossRefGoogle Scholar